Abstral

Abstral is a brand name of fentanyl, approved by the FDA in the following formulation(s):

ABSTRAL (fentanyl citrate - tablet; sublingual)

• 
  Manufacturer: PROSTRAKAN INC
  
  Approval date: January 7, 2011
  
  Strength(s): EQ 0.1MG BASE, EQ 0.2MG BASE, EQ 0.3MG BASE, EQ 0.4MG BASE ^[RLD], EQ 0.6MG BASE, EQ 0.8MG BASE
  

Has a generic version of Abstral been approved?

No. There is currently no therapeutically equivalent version of Abstral available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Abstral. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Fentanyl composition for the treatment of acute pain
  Patent 6,759,059
  Issued: July 6, 2004
  Inventor(s): Anders; Pettersson & Christer; Nystrom & Hans; Lennernas & Bo; Lennernas & Thomas; Hedner
  Assignee(s): Diabact AB
  A pharmaceutical composition for the treatment of acute pain by sublingual administration is described. The composition comprises an essentially water-free, ordered mixture of fentanyl or a pharmaceutically acceptable salt thereof in the form of microparticles which are adhered to the surface of carrier particles which are substantially larger than the particles of fentanyl, and are essentially water-soluble. In a preferred embodiment, the composition also contains a bioadhesion and/or mucoadhesion promoting agent. The invention also relates to the preparation of the composition, and to the use of the composition for the treatment of acute pain.
  
  Patent expiration dates:
  
  
  • September 24, 2019
    
    ✓ 
    Patent use: MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
    ✓ 
    Drug product
  
  



• 
  Pharmaceutical composition for the treatment of acute disorders
  Patent 6,761,910
  Issued: July 13, 2004
  Inventor(s): Anders; Pettersson & Christer; Nystrom
  Assignee(s): Diabact AB
  A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.
  
  Patent expiration dates:
  
  
  • September 24, 2019
    
    ✓ 
    Patent use: MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
    ✓ 
    Drug product
  
  



• 
  Pharmaceutical composition for the treatment of acute disorders
  Patent 7,910,132
  Issued: March 22, 2011
  Inventor(s): Pettersson; Anders & Nystrom; Christer
  Assignee(s): Orexo AB
  A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.
  
  Patent expiration dates:
  
  
  • September 24, 2019
    
    ✓ 
    Patent use: MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
    ✓ 
    Drug product
  
  

See also...

• Abstral Consumer Information (Drugs.com)
• Abstral Consumer Information (Wolters Kluwer)
• Abstral sublingual Consumer Information (Cerner Multum)
• Fentanyl Consumer Information (Drugs.com)
• Fentanyl Consumer Information (Wolters Kluwer)
• Fentanyl Lozenge Consumer Information (Wolters Kluwer)
• Fentanyl Patch Consumer Information (Wolters Kluwer)
• Fentanyl Soluble Film Consumer Information (Wolters Kluwer)
• Fentanyl Spray Consumer Information (Wolters Kluwer)
• Fentanyl Tablet Consumer Information (Wolters Kluwer)
• Fentanyl buccal Consumer Information (Cerner Multum)
• Fentanyl citrate oral transmucosal Consumer Information (Cerner Multum)
• Fentanyl nasal Consumer Information (Cerner Multum)
• Fentanyl sublingual Consumer Information (Cerner Multum)
• Fentanyl transdermal device Consumer Information (Cerner Multum)
• Fentanyl transdermal skin patch Consumer Information (Cerner Multum)
• Fentanyl Buccal mucosa, Oromucosal Advanced Consumer Information (Micromedex)
• Fentanyl Nasal Advanced Consumer Information (Micromedex)
• Fentanyl Transdermal Advanced Consumer Information (Micromedex)
• Fentanyl Citrate AHFS DI Monographs (ASHP)